Biogen (MEX:BIIB) Other Financing : MXN-306 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Biogen Other Financing?

Biogen's Other Financing for the three months ended in Jun. 2024 was MXN88 Mil.

Biogen's Other Financing for the trailing twelve months (TTM) ended in Jun. 2024 was MXN-306 Mil.

Biogen Other Financing Historical Data

The historical data trend for Biogen's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Financing Chart

Biogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Financing

Get a 7-Day Free Trial

148.99

-1,213.41

-2,383.73

95.53

-645.02

Biogen Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Financing	Get a 7-Day Free Trial															-	196.83	66.20	-657.21	87.94

Biogen Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-306 Mil.

Biogen Other Financing Related Terms

Thank you for viewing the detailed overview of Biogen's Other Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Biogen Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » Other Financing

Comparable Companies

Traded in Other Exchanges

BIIB:USA 1BIIB:Italy 0R1B:UK IDP:Germany BIIB34:Brazil BIIB:Austria BIIB:Argentina

Address

225 Binney Street, Cambridge, MA, USA, 02142

Website

https://www.biogen.com

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.